NO20073453L - Fremgangsmater for a forbedre strukturen og funksjonen av arterioler - Google Patents

Fremgangsmater for a forbedre strukturen og funksjonen av arterioler

Info

Publication number
NO20073453L
NO20073453L NO20073453A NO20073453A NO20073453L NO 20073453 L NO20073453 L NO 20073453L NO 20073453 A NO20073453 A NO 20073453A NO 20073453 A NO20073453 A NO 20073453A NO 20073453 L NO20073453 L NO 20073453L
Authority
NO
Norway
Prior art keywords
arterioles
function
improving
methods
kidneys
Prior art date
Application number
NO20073453A
Other languages
English (en)
Norwegian (no)
Inventor
Alan M Fogelman
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO20073453L publication Critical patent/NO20073453L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20073453A 2004-12-06 2007-07-04 Fremgangsmater for a forbedre strukturen og funksjonen av arterioler NO20073453L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63431804P 2004-12-06 2004-12-06
PCT/US2005/044422 WO2006063132A2 (fr) 2004-12-06 2005-12-06 Procedes pour l'amelioration de la structure et de la fonction d'arterioles

Publications (1)

Publication Number Publication Date
NO20073453L true NO20073453L (no) 2007-08-28

Family

ID=36578567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073453A NO20073453L (no) 2004-12-06 2007-07-04 Fremgangsmater for a forbedre strukturen og funksjonen av arterioler

Country Status (15)

Country Link
US (2) US7579319B2 (fr)
EP (1) EP1827472A4 (fr)
JP (2) JP2008522980A (fr)
KR (1) KR20070089996A (fr)
CN (1) CN101115496B (fr)
AU (1) AU2005314043A1 (fr)
BR (1) BRPI0517148A (fr)
CA (1) CA2595067A1 (fr)
IL (1) IL183689A (fr)
MX (1) MX2007006750A (fr)
NO (1) NO20073453L (fr)
NZ (1) NZ555826A (fr)
RU (1) RU2414236C2 (fr)
WO (1) WO2006063132A2 (fr)
ZA (1) ZA200705489B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
NZ541504A (en) * 2002-11-13 2009-04-30 Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
CN101076541A (zh) * 2004-07-16 2007-11-21 塔夫茨大学信托人 载脂蛋白a1模拟物及其用途
EP1799242A4 (fr) * 2004-09-16 2009-11-11 Univ California Peptides de type g et autres agents permettant d'ameliorer l'atherosclerose et d'autres pathologies
CA2595067A1 (fr) 2004-12-06 2006-06-15 The Regents Of The University Of California Procedes pour l'amelioration de la structure et de la fonction d'arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP2368561B1 (fr) * 2005-04-29 2013-12-04 The Regents of The University of California Peptides et mimétiques de peptides pour traiter des pathologies caractérisées par une réponse inflammatoire
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
DK2682400T5 (da) 2007-08-28 2017-11-27 Uab Research Foundation Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse
WO2011113604A1 (fr) * 2010-03-17 2011-09-22 Universität Regensburg Peptides ou anticorps se liant à une protéine à activité inhibitrice du mélanome
WO2013033260A1 (fr) 2011-08-29 2013-03-07 The Regents Of The University Of California Utilisation de molécules associées au hdl pour traiter et prévenir des états pro-inflammatoires
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
CN103740661B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
CN103740659B (zh) * 2012-05-10 2015-06-03 江南大学 一种提高酶热稳定性的方法
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
US10905736B2 (en) 2016-09-28 2021-02-02 The Regents Of The University Of California Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
DE102017114262A1 (de) 2017-06-27 2018-12-27 Salzgitter Flachstahl Gmbh Stahllegierung mit verbesserter Korrisionsbeständigkeit bei Hochtemperaturbeanspruchung und Verfahren zur Herstellung von Stahlband aus dieser Stahllegierung
US11410246B2 (en) 2019-06-06 2022-08-09 Salus Finance, LLC System and method for consolidation, reconciliation and payment management
WO2021211847A1 (fr) * 2020-04-15 2021-10-21 Lactocore, Inc. Peptides synthétiques pour la modulation du récepteur 5 du glutamate métabotropique

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
HU185263B (en) 1981-06-12 1984-12-28 Richter Gedeon Vegyeszet Process for producing peptides effective on the immuncontroll analogous with the tp5
CH661438A5 (it) 1984-04-09 1987-07-31 Seuref Ag Composizioni farmaceutiche ad azione antianossica e metabolica cerebrale.
US4618600A (en) 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
US5258368A (en) 1984-04-19 1993-11-02 Scios Nova, Inc. Atrial natriuretic/vasodilator peptide compounds
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
NZ229004A (en) 1988-05-19 1993-09-27 Immunobiology Res Inst Inc Tetrapeptides having t cell helper acitivity
US5480869A (en) 1990-01-09 1996-01-02 The Regents Of The University Of California Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
DE4101895C1 (fr) 1991-01-23 1991-12-05 Forschungszentrum Juelich Gmbh, 5170 Juelich, De
WO1993025581A1 (fr) 1992-06-12 1993-12-23 N.V. Innogenetics S.A. Nouveaux peptides et proteines, leur procede de preparation et leur utilisation en tant qu'accepteurs de cholesterol
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
EP0621284A4 (fr) 1992-08-14 1996-06-12 Shino Test Corp PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS.
JP3401005B2 (ja) 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
EP0770091B1 (fr) 1994-05-12 2000-03-01 Balazs Sarkadi Composes servant a annihiler la resistance a des agents therapeutiques medicamenteux
US5595973A (en) 1994-09-12 1997-01-21 Biomeasure Incorporated Protection of hemopoietic cells during chemotherapy or radiotherapy
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
DK0853480T3 (da) 1995-09-09 2003-05-05 Hoffmann La Roche Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer
US6277826B1 (en) 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
NZ331980A (en) 1996-03-29 2000-09-29 Helmut Hauser Amphipathic peptides with alpha helices as cholesterol and other lipid uptake inhibitors
US6555651B2 (en) 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
AU7100898A (en) 1997-04-02 1998-10-22 Brigham And Women's Hospital Means of ascertaining an individual's risk profile for atherosclerotic disease
WO1998046625A1 (fr) 1997-04-11 1998-10-22 Warner-Lambert Company Inhibiteurs dipeptidiques de la farnesyltransferase
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
EP0873687B2 (fr) 1997-04-24 2006-04-26 Chemoxal Sa Composition désinfectante et fongicide à base d'acide péracétique et d'un oxyde d'amine
IN185761B (fr) 1997-05-13 2001-04-28 Council Scient Ind Res
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
CA2301634A1 (fr) 1997-07-15 1999-01-28 Pradeep Ghosh Determination de la consommation d'alcool au moyen de l'acide sialique/apo j
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US6191151B1 (en) * 1997-11-12 2001-02-20 Howard M. Zik Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
US6320017B1 (en) * 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
US20030077641A1 (en) 1998-03-11 2003-04-24 Laskowitz Daniel T. Methods of suppressing microglial activation and systemic inflammatory responses
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US6846636B1 (en) 1998-05-15 2005-01-25 American National Red Cross Methods and compositions for HDL holoparticle uptake receptor
US6019739A (en) 1998-06-18 2000-02-01 Baxter International Inc. Minimally invasive valve annulus sizer
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6451303B1 (en) 1998-10-13 2002-09-17 Chiron Corporation Method of treating coronary artery disease by administering a recombinant FGF
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6228989B1 (en) 1998-11-13 2001-05-08 The Regents Of The University Of California Peptide substrates phosphorylated by P21-activated protein kinase
AU3116800A (en) 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
US6332017B1 (en) 1999-01-25 2001-12-18 Vanderbilt University System and method for producing pulsed monochromatic X-rays
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
GB9911689D0 (en) 1999-05-19 1999-07-21 Medical Res Council Refolding method
US6727063B1 (en) 1999-09-10 2004-04-27 Millennium Pharmaceuticals, Inc. Single nucleotide polymorphisms in genes
JP2003513622A (ja) 1999-11-02 2003-04-15 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １９個のヒト分泌タンパク質
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US6596544B1 (en) 2000-03-31 2003-07-22 The Regents Of The University Of California Functional assay of high-density lipoprotein
US20030040505A1 (en) 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
ES2260219T3 (es) * 2000-04-21 2006-11-01 Amgen Inc. Derivados de peptidos apo-ai/aii.
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
CA2415054A1 (fr) 2000-07-13 2002-01-31 Dilip Wagle Thiazoliums et imidazoliums substitues par le cyanomethyle et traitements de troubles associes au vieillissement proteique
DE60128475T2 (de) 2000-07-25 2008-02-07 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1186299A1 (fr) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnostic, prévention et/ou traitement d' athérosclérose, infections et perturbations du système immunitaire
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
JP2002226457A (ja) 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US6815426B2 (en) 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2002085899A1 (fr) 2001-04-19 2002-10-31 Vertex Pharmaceuticals Incorporated Heterocyclyl-dicarbamides en tant qu'inhibiteurs de caspase
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
US20030125260A1 (en) 2001-10-31 2003-07-03 Fortuna Haviv Tetra-and pentapeptides having antiangiogenic activity
US7308303B2 (en) * 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
AU2003202737A1 (en) 2002-02-28 2003-09-09 Koninklijke Philips Electronics N.V. Method for controlling the mode of an electronic application
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7026295B2 (en) 2002-12-04 2006-04-11 Agennix Incorporated Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
US20060217298A1 (en) 2003-02-04 2006-09-28 Srivastava Pramod K Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins
US20050070996A1 (en) 2003-04-08 2005-03-31 Dinh Thomas Q. Drug-eluting stent for controlled drug delivery
US6936961B2 (en) 2003-05-13 2005-08-30 Eastman Kodak Company Cascaded organic electroluminescent device having connecting units with N-type and P-type organic layers
US7291590B2 (en) 2003-06-12 2007-11-06 Queen's University At Kingston Compositions and methods for treating atherosclerosis
CA2549236C (fr) 2003-12-05 2017-06-13 The Cleveland Clinic Foundation Marqueurs de risque pour maladies cardiovasculaires
CN101076541A (zh) 2004-07-16 2007-11-21 塔夫茨大学信托人 载脂蛋白a1模拟物及其用途
EP1799242A4 (fr) 2004-09-16 2009-11-11 Univ California Peptides de type g et autres agents permettant d'ameliorer l'atherosclerose et d'autres pathologies
CA2595067A1 (fr) 2004-12-06 2006-06-15 The Regents Of The University Of California Procedes pour l'amelioration de la structure et de la fonction d'arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP2368561B1 (fr) 2005-04-29 2013-12-04 The Regents of The University of California Peptides et mimétiques de peptides pour traiter des pathologies caractérisées par une réponse inflammatoire
RU2007148927A (ru) 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment

Also Published As

Publication number Publication date
EP1827472A4 (fr) 2012-09-05
RU2007125589A (ru) 2009-01-20
IL183689A (en) 2010-12-30
CN101115496B (zh) 2012-03-07
JP2012082232A (ja) 2012-04-26
BRPI0517148A (pt) 2008-09-30
CN101115496A (zh) 2008-01-30
US20060234908A1 (en) 2006-10-19
US7579319B2 (en) 2009-08-25
KR20070089996A (ko) 2007-09-04
EP1827472A2 (fr) 2007-09-05
WO2006063132A3 (fr) 2006-08-17
US8236754B2 (en) 2012-08-07
RU2414236C2 (ru) 2011-03-20
IL183689A0 (en) 2007-09-20
MX2007006750A (es) 2007-11-23
JP2008522980A (ja) 2008-07-03
NZ555826A (en) 2009-11-27
US20090286741A1 (en) 2009-11-19
AU2005314043A1 (en) 2006-06-15
ZA200705489B (en) 2008-09-25
WO2006063132A2 (fr) 2006-06-15
CA2595067A1 (fr) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20073453L (no) Fremgangsmater for a forbedre strukturen og funksjonen av arterioler
EA200700058A1 (ru) Соединения, композиции и способы их использования
EP1605752A4 (fr) Composes, compositions et methodes
WO2007078839A3 (fr) Composes, compositions et methodes
DK3357911T3 (da) Prolylhydroxylaseinhibitorer og fremgangsmåder til anvendelse
HK1085461A1 (en) Compounds, compositions and methods of treatment for heart failure
WO2007070626A3 (fr) Entites chimiques, compositions et procedes
DK1532269T3 (da) 1L1RL-1 som markør for kardiovaskulær sygdom
WO2008154033A3 (fr) Configuration cardiaque pour améliorer la fonction diastolique
WO2005049084A3 (fr) Inhibition de canaux trp comme traitement contre l'hypertrophie et l'insuffisance cardiaques
NO20075764L (no) Kombinert anvendelse av prostaglandinforbindelse og protonpumpeinhibitor til behandling av forstyrrelser i mage- og tarmkanalen
WO2004032852A3 (fr) Procedes permettant de traiter l'arythmie cardiaque et de prevenir la mort due a l'arythmie cardiaque au moyen d'antagonistes du ngf
TW200500361A (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
NO20082298L (no) Kaliumkanalinhibitorer
EA201071293A1 (ru) Композиция для укладки волос
WO2003059258A3 (fr) Compositions et methodes permettant de traiter l'insuffisance cardiaque
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
WO2003059265A3 (fr) Compositions et procedes de traitement de l'insuffisance cardiaque
NO20074805L (no) Fremgangsmate for a identifisere PDE11-modulatorer
NO20080829L (no) Sammensetninger og metoder for kontroll av angiogenese med cupredoxiner
NO20085252L (no) Imidazolidinon Kv1.5 kaliumkanalinhibitorer
WO2007114925A3 (fr) Canaux à deux p utilisés comme cible thérapeutique pour la protection contre l'ischémie myocardique et comme adjuvant en chirurgie cardiaque
NO20090761L (no) Sammensetning og fremgangsmate for behandling av tumorer
WO2007015775A3 (fr) Inhibiteurs des canaux potassiques
WO2021222421A3 (fr) Opsine à fonction échelon ultrasensible pour une stimulation optogénétique minimalement invasive

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application